A 19-year-old Japanese male with a BMI of 55.4 kg/m 2 who also had liver dysfunction, dyslipidemia and hyperuricemia underwent repeated intragastric balloon therapy. The percent excess weight loss was 22.5% at the first balloon removal and 28.6% at the second balloon removal. The hepatic dysfunction resolved after the second balloon therapy, however, the dyslipidemia and hyperuricemia did not improve. The Japanese population is regarded as a high-risk race for obesity-related diseases at lower BMI values, and morbidly obese Japanese patients may need more serious weight reduction protocols to improve the comorbidities than similarly obese Americans or Europeans.
Introduction
The prevalence of overweight people is increasing around the world. In parallel, obesity-related diseases such as type 2 diabetes, hypertension, dyslipidemia, respiratory disorders, and osteoarthropathy are also increasing in prevalence and becoming major public health problems. The outcomes of diet therapy, exercise, behavioral therapy and medication are still not satisfactory, although bariatric surgery has been shown to result in substantial, long-term weight reduction in Europe and in the United States. Meanwhile, the Japanese population is regarded as a high-risk race for obesity-related diseases at lower BMI values, but bariatric surgery including intragastric balloon therapy has not yet become a popular method in Japan. Kawamura and Ochiai (1) introduced the gastric bypass in 1982 as the first bariatric surgery in Japan. Kasama et al (2) started laparoscopic Roux-en-Y gastric bypass from 2002. Intragastric balloon therapy was introduced to Japan by Ohta et al in 2004 (3) . Ohta et al also evaluated the safety and efficacy of laparoscopic sleeve gastrectomy for Japanese patients (4). To date there are only a few reports on the experience of using intragastric balloon therapy in Japanese patients.
Case Report
A 19-year-old asymptomatic man was admitted to our hospital because of hepatic dysfunction, dyslipidemia and hyperuricemia detected incidentally during a routine medical checkup. He was morbidly obese (class 3 obesity according to WHO criteria), weighing 164 kilograms, and 172.0 centimeters tall. The body mass index was 55.4 kg/m 2 , and the excess weight was 98.9 kilograms. He chose the minimally invasive treatment, and intragastric balloon therapy was undertaken (BIB , Inamed, Health-Allergan Medical, Santa Barbara, CA, USA) ( Fig. 1) for 240 days and his weight was reduced by 22.3 kilograms, which represented a percent excess weight loss (%EWL: excess weight loss) of 22.5%. In principle, an intragastric balloon is removed within 180 days because of product durability, but the patient's schedule of school did not permit him to be admitted to our hosGastroenterology Division, Yokohama City University School of Medicine, Japan and Department of Endocrinology and Metabolism, Yokohama City University School of Medicine, Japan pital until 240 days after the placement. One month after the balloon removal, the patient was reluctant to undergo bariatric surgery and chose a second balloon insertion. Intragastric balloon therapy was undertaken again for 217 days. The weight loss following the second balloon therapy was 6.0 kilograms, the total weight loss was 28.3 kilograms, and the %EWL was 28.6% (Fig. 2) . The hepatic dysfunction was resolved, however, dyslipidemia and hyperuricemia did not improve (Table 1) .
Discussion
After intragastric balloon therapy, recurrent weight gain is one of the most important problems and the mean %EWL falls by 13 -18% within one year of the balloon removal (5, 6). As compared with that in mildly obese patients (BMI <39.9 kg/m 2 ), the outcome of intragastric balloon therapy in patients with class 3 obesity (BMI >40 kg/m 2 , as in the present case) has been reported to be worse with a mean %EWL at removal of the balloon of 25.9% vs. 42.3%, and a mean %EWL at one year after the removal of the balloon of 20.4% vs. 27.9% (3). Therefore, intragastric balloon therapy is regarded to be more appropriate for patients with relatively mild obesity. Previous reports showed that 2 consecutive balloon therapies (6) and repeated balloon therapies (7) achieved good results after 12 months of treatment, and multiple balloon therapies were effective maintenance treatment to control body weight in Prader-Willi syndrome patients when treatment was started in early childhood (8) .
In the present patient, diagnosed as a class 3 obesity patient with a BMI of 55.4 kg/m 2 , intragastric balloon therapy resulted in a good outcome, with a %EWL of 22.5% at 8 months after the first balloon removal. While second intragastric balloon therapies have been reported to yield smaller rates of weight loss, repeat treatment likely plays a role as maintenance treatment for patients with recurrent weight gain who feel uncomfortable undergoing bariatric surgery.
Regarding obesity-related diseases, the present patient had 3 comorbidities: liver dysfunction, dyslipidemia and hyperuricemia before the balloon therapy. The liver dysfunction showed no remarkable change at the first balloon removal, however, it improved substantially following the second balloon removal. On the other hand, no improvement in the dyslipidemia or hyperuricemia was noted even after 2 balloon therapies. Previous reports on comorbidities at the time of balloon removal indicate relatively high improvement rates (including resolution) of the comorbidities: 80 -93.7% for hypertension, 86.9-100% for diabetes, 51.9 -86% for dyslipidemia, and 100% for liver dysfunction, with no reports for hyperuricemia (3, 6, 9) (Table 2 ). The present patient showed poor improvement of the comorbidities following balloon therapy despite the successful weight reduction; the following reasons are proposed for this lack of marked improvement of the comorbidities in our patient: First, this patient was morbidly obese, with a BMI of 55.4 kg/m 2 before treatment, which was significantly higher than the mean BMI of patients (37.6-44.4 kg/m 2 ) included in previous reports investigating the improvement of comorbidities following treatment for obesity (3, 6, 9) . Secondly, Japanese patients have been considered to develop obesity-related diseases at a lower body weight than European subjects: the prevalence of individuals with a BMI of 30 kg/m 2 is only 3% in Japan and more than 30% in the United States, while the prevalence of glucose intolerance and dyslipidemia is 10% in Japan, almost the same as that in the United States (10) . Considering the improvement of the liver dysfunction following the therapy in the present patient, it is possible that he might need more weight reduction to obtain improvement of the other comorbidities.
Conclusion
Repeat intragastric balloon therapy can play a role as maintenance treatment for patients showing recurrent weight gain. However, the Japanese population has been considered as a high-risk group for obesity-related diseases at lower body weights than European people. Japanese patients with morbid obesity may need more serious weight reduction protocols to improve the comorbidities than similarly obese Americans or Europeans. We need more experience with intragastric balloon therapy in morbidly obese Japanese patients to determine how much weight reduction would be necessary for improvement of the comorbidities.
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